BARCELONA – Molomics Biotech is seeking investment of €400K to fund its fight against Parkinson’s. The company’s investment round via the Capital Cell platform is all about progressing its AI-inspired treatment for the control o fLevodopa Induced Dyskinesia, a ‘movement disorder that can cause a significant physical disability’.
“We have decided to collaborate with Capital Cell to allow anyone in Spain to become a partner of Molomics and support the fight against Parkinson’s, which, if successful, could lead to a lucrative return on investment,” said Jascha Blobel, CEO of Molomics, which is based at Barcelona Science Park.
Discover more about Molomics Biotech’s latest funding round to support innovation that tackles a disease which destroys the lives of millions worldwide.
